5 Metabolic liver disease In a 240-week phase 3 clinical trial of 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2-F3 (mean BMI 34.6), semaglutide 2.4 mg weekly improved liver histology (Non-alcoholic Fatty Liver Disease Activity Score, inflammation, and ballooning and steatosis) in the first 800 participants over 72 weeks
The frequency of injections can be tailored to your specific needs, whether its an initial series of treatments for a noticeable boost or a monthly maintenance plan to sustain your results
Irshad will help create a personalized Xeomin treatment program to relax your dynamic wrinkles and give you a more youthful appearance
Learn more about our 1-year same-as-cash financing and get answers to your coverage questions easily
"FDA's June 2026 Compounding Proposal" refers to the FDA's publicly announced proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period open through June 2026 - this is a factual regulatory event documented in the Federal Register and at FDA.gov, not a determination specific to FeelGood